Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

Company Overview

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company develops medicines designed to regulate gene expression by targeting the chromatin regulatory system, a network of proteins and complexes that controls how genetic information is organized and used within cells.

Foghorn’s discovery platform, known as Gene Traffic Control, is intended to identify drug targets within chromatin-remodeling complexes and develop selective small-molecule therapies. Its research has primarily focused on oncology, including cancers associated with abnormalities in chromatin regulators. The company has advanced investigational programs such as FHD-286, a small-molecule inhibitor designed to affect chromatin-remodeling ATPases, and FHD-609, a targeted protein degrader directed at the BRD9 protein.

Founded in 2015, Foghorn has collaborated with pharmaceutical and biotechnology companies to pursue treatments based on its chromatin biology platform. The company’s drug candidates are investigational and have been evaluated in clinical studies for selected hematologic malignancies and solid tumors. Foghorn is led by President and Chief Executive Officer Adrian Gottschalk.

Key Stats

• Today's Range: $4.08 to $4.23
• 50-Day Range: $4.12 to $7.07
• 52-Week Range: $3.27 to $7.61
• Volume: 354,919 shs
• Average Volume: 409,017 shs
• Market Capitalization: $247.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.67
• Consensus Rating: Moderate Buy

Foghorn Therapeutics Stock Analysis - MarketRank™

Foghorn Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 558th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Foghorn Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Foghorn Therapeutics has a consensus price target of $11.43, representing about 174.1% upside from its current price of $4.17.

Amount of Analyst Coverage

Foghorn Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Foghorn Therapeutics are expected to decrease in the coming year, from ($0.81) to ($0.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Foghorn Therapeutics is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Foghorn Therapeutics is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.65% of the float of Foghorn Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Foghorn Therapeutics has a short interest ratio ("days to cover") of 4.64.

Change versus previous month

Short interest in Foghorn Therapeutics has recently increased by 10.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Foghorn Therapeutics does not currently pay a dividend.

Dividend Growth

Foghorn Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Foghorn Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Foghorn Therapeutics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for FHTX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.02% of the stock of Foghorn Therapeutics is held by insiders.

Percentage Held by Institutions

61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/17/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FHTX
• CIK: 1822462
• Web: foghorntx.com
• Phone: 617-586-3100
• Fax: N/A
• Employees: 106
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Foghorn Therapeutics: $11.67
• High Price Target: $13.00
• Low Price Target: $10.00
• Potential Upside/Downside: +179.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.28 million
• Net Margins: -175.78%
• Pretax Margin: -175.78%
• Return on Equity: N/A
• Return on Assets: -31.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.36
• Quick Ratio: 3.36

Sales & Book Value

• Annual Sales: $30.91 million
• Price / Sales: 8.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.92) per share
• Price / Book: -2.17

Miscellaneous

• Outstanding Shares: 59,380,000
• Free Float: 54,028,000
• Market Cap: $247.61 million
• Optionable: Optionable
• Beta: 2.86